Therapy Area topics
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
New Amsterdam wants to prove that the ill-fated mechanism has a role in cardiovascular disease – and this time it’s all about the bad cholesterol.
New devices are coming, but the real advances will involve combinations.
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Bayer dumps Atara, Precigen prepares for a fire sale and Tmunity struggles to find direction. Should investors still be excited about cell therapy?
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
Positive data result in positive share price movements – something of a novelty in the current market.
Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.
But pressure is on the shingles vaccine as the consumer spin-off approaches.
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.